The first Theravance Biopharma trade was made in Q2 2014.
Since then Chuck Royce bought shares two more times and sold shares on eleven occasions. The investor completely sold their stake between Q4 2015 and Q4 2024.
Avg closing price
Price range
Sold -59 Thousand shares
Q4 2024
Avg closing price
$9.12
Price range
$7.93
-
$10.08
Sold 36.8% shares (-34.3 Thousand shares)
Q4 2020
Avg closing price
$17.95
Price range
$14.89
-
$20.16
Sold 9.7% shares (-10 Thousand shares)
Q2 2017
Avg closing price
$38.45
Price range
$35.46
-
$42.56
Sold 13.0% shares (-15.5 Thousand shares)
Q4 2016
Avg closing price
$31.02
Price range
$24.57
-
$38.58
Sold 55.3% shares (-147 Thousand shares)
Q3 2016
Avg closing price
$27.84
Price range
$22.26
-
$36.97
Sold 26.7% shares (-97 Thousand shares)
Q2 2016
Avg closing price
$21.59
Price range
$17.45
-
$24.20
Sold 11.2% shares (-45.9 Thousand shares)
Q1 2016
Avg closing price
$16.36
Price range
$13.35
-
$18.80
Sold 20.5% shares (-105 Thousand shares)
Q4 2015
Avg closing price
$15.87
Price range
$11.13
-
$19.51
Increased shares by 5.5% (+27 Thousand shares)
Q3 2015
Avg closing price
$12.73
Price range
$10.88
-
$14.80
Sold 3.8% shares (-19.2 Thousand shares)
Q2 2015
Avg closing price
$15.51
Price range
$12.57
-
$18.63
Sold 11.9% shares (-68.5 Thousand shares)
Q1 2015
Avg closing price
$18.33
Price range
$14.70
-
$21.73
Increased shares by 504.6% (+479 Thousand shares)
Q4 2014